Flow cytometry was used to evaluate the presence of circulating tumor cells in the WHIM20 PDX model and found that mice with PDX tumors grown with obASCs had no significant difference in human (HLA1+) circulating tumor cells (CTCs); however CTCs from tumors grown with obASCs demonstrated a trend of enrichment for the breast cancer stem cell markers CD44+CD24− (Figure 1C). The gene discussed is CD44; the disease is breast cancer.